FDA Grants Fast Track to Alterity’s ATH434 for Multiple System Atrophy
Alterity Therapeutics has received Fast Track designation from the U.S. FDA for ATH434, a treatment for Multiple System Atrophy...
Alterity Therapeutics has received Fast Track designation from the U.S. FDA for ATH434, a treatment for Multiple System Atrophy...
Regeneration Biomedical, Inc. (RBI) announced positive interim results from its Phase 1 clinical trial of a novel Alzheimer’s diseaseAlzheimer’s...
Theratechnologies presented two posters at the 19th Annual American Conference for the Treatment of HIV (ACTHIV 2025), focusing on...
Recursion Pharmaceuticals announced preliminary results from its Phase 1b/2 TUPELO trial of REC-4881, a MEK1/2 inhibitor for Familial Adenomatous...
Spherix Global Insights’ recent study of US hematologists reveals growing confidence in gene therapies like Casgevy and Lyfgenia for...
Scilex Holding Company (Nasdaq: SCLX) will present a post-hoc analysis of the C.L.E.A.R. trial at the 27th Annual Meeting...
4D Molecular Therapeutics (4DMT) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its product 4D-150,...
Design Therapeutics announced positive Phase 1 trial data for DT-168, an eye drop formulated to treat Fuchs endothelial corneal...
Anavex Life Sciences Corp. has completed enrollment in its Phase 2 clinical trial (ANAVEX3-71-SZ-001) of ANAVEX®3-71 for schizophrenia treatment....
Bio-Path Holdings announced positive preclinical results for BP1001-A, a potential obesity and Type 2 diabetes treatment. The drug candidate...